Cargando…

Phase 3, open-label, randomized study comparing 3-monthly with monthly goserelin in pre-menopausal women with estrogen receptor-positive advanced breast cancer

BACKGROUND: Monthly goserelin 3.6 mg dosing suppresses estradiol (E2) production and has proven efficacy in pre-menopausal women with estrogen receptor (ER)-positive breast cancer. This non-inferiority study evaluated the efficacy and safety of 3-monthly goserelin 10.8 mg compared with monthly goser...

Descripción completa

Detalles Bibliográficos
Autores principales:	Noguchi, Shinzaburo, Kim, Hee Jeong, Jesena, Anita, Parmar, Vani, Sato, Nobuaki, Wang, Hwei-Chung, Lokejaroenlarb, Santi, Isidro, Jofel, Kim, Ku Sang, Itoh, Yohji, Shin, Eisei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Japan 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4999470/ https://www.ncbi.nlm.nih.gov/pubmed/26350351 http://dx.doi.org/10.1007/s12282-015-0637-4

Ejemplares similares

Agoraphobia and Follicle-Stimulating Hormone Levels between Tamoxifen and Goserelin versus Tamoxifen Alone in Premenopausal Hormone Receptor-Positive Breast Cancer: A 12-Month Prospective Randomized Study
por: Heo, Jung-Yoon, et al.
Publicado: (2017)

A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer
por: Shiba, Eiichi, et al.
Publicado: (2015)

Clinicopathological Characteristics of Estrogen Receptor‐(3‐positive Human Breast Cancers
por: Miyoshi, Yasuo, et al.
Publicado: (2001)

Update on the management of prostate cancer with goserelin acetate: patient perspectives
por: Wilson, Shandra
Publicado: (2009)

Goserelin Ovarian Ablation Failure in Premenopausal Women With Breast Cancer
por: Gupta, Aanchal, et al.
Publicado: (2021)

Comparison of quality of life between 2-year and 3-or-more-year administration of leuprorelin acetate every-3-months depot in combination with tamoxifen as adjuvant endocrine treatment in premenopausal patients with endocrine-responsive breast cancer: a randomized controlled trial
por: Ohashi, Yasuo, et al.
Publicado: (2017)

Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer
por: Hasan, J, et al.
Publicado: (2005)

Goserelin (Zoladex) in premenopausal advanced breast cancer: duration of response and survival.
por: Dixon, A. R., et al.
Publicado: (1990)

Durable Response of Androgen Receptor-Positive Male Breast Cancer to Goserelin
por: Abdel Azim, Hamdy, et al.
Publicado: (2018)

Unsuspected Skin Metastasis of Adenocarcinoma of the Prostate in a Patient on Goserelin (Zoladex)
por: Mbaeri, Timothy Uzoma, et al.
Publicado: (2018)

Goserelin-Induced Chemical Burn: A Case Report and Review of the Literature
por: Mahadevan, Aditya, et al.
Publicado: (2023)

Goserelin (Zoladex™) – its role in early breast cancer in pre- and perimenopausal women
por: Jonat, W
Publicado: (2002)

Goserelin (Zoladex™) – its role in early breast cancer in pre- and perimenopausal women
por: Jonat, W
Publicado: (2001)

A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancer.
por: Lind, M. J., et al.
Publicado: (1992)

Long-term Effectiveness of Adjuvant Goserelin in Premenopausal Women With Early Breast Cancer
por: Hackshaw, Allan, et al.
Publicado: (2009)

Primary Mediastinal Choriocarcinoma in an Elderly Patient with Concurrent Goserelin-Treated Prostate Adenocarcinoma
por: Røge, Rasmus, et al.
Publicado: (2019)

FATHER–CHILD INTERACTIONS AT 3 MONTHS AND 24 MONTHS: CONTRIBUTIONS TO CHILDREN'S COGNITIVE DEVELOPMENT AT 24 MONTHS
por: Sethna, Vaheshta, et al.
Publicado: (2017)

No supra-additive effects of goserelin and radiotherapy on clonogenic survival of prostate carcinoma cells in vitro
por: Hermann, Robert M, et al.
Publicado: (2007)

Reinduction of Hormone Sensitivity to Goserelin following Chemotherapy with Vinorelbine in Castration-Resistant Prostate Cancer
por: Grenader, Tal, et al.
Publicado: (2010)

Treatment of leiomyomatosis peritonealis disseminata with goserelin acetate: A case report and review of the literature
por: Yang, Jia-Wen, et al.
Publicado: (2021)

Pharmacological and toxicological studies of a novel goserelin acetate extended-release microspheres in rats
por: Yutong, Mao, et al.
Publicado: (2023)

Oxaliplatin (3 months v 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07
por: Kim, Seung Tae, et al.
Publicado: (2022)

3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study
por: Wu, Xiaojun, et al.
Publicado: (2021)

Cost-utility analysis of adjuvant goserelin (Zoladex) and adjuvant chemotherapy in premenopausal women with breast cancer
por: Cheng, Tsui Fen, et al.
Publicado: (2012)

Both Castration and Goserelin Acetate Ameliorate Myocardial Ischemia Reperfusion Injury and Apoptosis in Male Rats
por: Hadi, Najah R., et al.
Publicado: (2014)

The affect of goserelin on the QoL of women having chemotherapy for EBC: Results from the OPTION trial
por: R, Leonard, et al.
Publicado: (2020)

Identification of predictors based on drug targets highlights accurate treatment of goserelin in breast and prostate cancer
por: Zhao, Yue, et al.
Publicado: (2021)

SUN-537 Progesterone Therapy and Serum Sclerostin Levels in Healthy Menopausal Women: A 3-month Randomized, Placebo Controlled Clinical Trial
por: Yang, Yuebo, et al.
Publicado: (2019)

Patients’ Preferences for 3 Months vs 6 Months of Adjuvant Chemotherapy for Colon Cancer
por: Blinman, Prunella, et al.
Publicado: (2020)

How motor elements at 3 months influence motor performance at the age of 6 months
por: Gajewska, Ewa, et al.
Publicado: (2021)

A 9-Month-Old Boy With “3 Months of Croup” a Devil Inside
por: Sah, Amit, et al.
Publicado: (2022)

The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer.
por: Stein, R. C., et al.
Publicado: (1990)

Hormonal treatment of pancreatic carcinoma: a phase II study of LHRH agonist goserelin plus hydrocortisone.
por: Philip, P. A., et al.
Publicado: (1993)

Goserelin promotes the apoptosis of epithelial ovarian cancer cells by upregulating forkhead box O1 through the PI3K/AKT signaling pathway
por: Zhang, Ning, et al.
Publicado: (2018)

Short-term efficacy of 1-month and 3-month gonadotropin-releasing hormone agonist depots in girls with central precocious puberty
por: Jeon, Min Jin, et al.
Publicado: (2021)

Impact of 3 months of detraining after high intensity exercise on menopause-related symptoms in early postmenopausal women – results of the randomized controlled actlife project
por: Jungmann, Sophia, et al.
Publicado: (2023)

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
por: Mathews, Maju, et al.
Publicado: (2019)

F230. COMPARISON OF PALIPERIDONE PALMITATE 3-MONTH AND PALIPERIDONE PALMITATE 1-MONTH FORMULATION FOR NEGATIVE SYMPTOMS IN SCHIZOPHRENIA: A PHASE 3 NON-INFERIORITY STUDY
por: Mathews, Maju, et al.
Publicado: (2018)

Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study
por: Gopal, Srihari, et al.
Publicado: (2020)

Post-stroke cognitive impairment at 3 months
por: Sundar, Uma, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_ff8inqqjrepqqmqgi0l6p0e71h